Introduction
============

The transmembrane emp24 domain (TMED) protein family is involved in the vesicular trafficking of proteins and innate immune signaling ([@B30]; [@B36]). TMED proteins contain a Golgi dynamics domain and function in Golgi dynamics and intracellular protein trafficking ([@B14]; [@B2]; [@B22];[@B15]). Recent studies have implicated TMED7 in the regulation of TLR4 signaling ([@B24]; [@B7]; [@B20]), and TMED1 is involved in the ST2L-IL33 axis ([@B6]). In addition, a recent study showed that TMED3 overexpression was significantly correlated with an aggressive phenotype of HCC and poor prognosis ([@B36]). In HCC, TMED3 promotes metastasis through IL-11/STAT3 signaling. However, the clinical significance of TMED3 and its role in other malignancies are unknown.

Kidney cancer is among the top 10 cancers, and 30% of patients with kidney cancer present with metastatic disease ([@B23]). Renal cell carcinoma (RCC) accounts for 90% of kidney cancers ([@B5]; [@B27]), and clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer ([@B28]). However, 30% of patients with ccRCC have been diagnosed with advanced cancer ([@B16]), and the therapeutics available for renal cancer is not very effective. Therefore, there is a great need for new drugs and biomarkers for ccRCC.

Thus far, the prognostic significance of TMED3 in ccRCC is unknown. In this study, we present the first data on *TMED3* expression in ccRCC in a well-defined cohort from the TGCA ([@B3]; [@B1]) and ICGC ([@B13]) primary ccRCC cohorts. The statistical analysis suggested that TMED3 could be a useful prognostic factor in ccRCC.

Materials and Methods {#s1}
=====================

Patient Data Acquisition and Statistical Analysis
-------------------------------------------------

The data were downloaded from TCGA ([@B3]; [@B1]) and ICGC ([@B13]) from the ICGC data portal ^[1](#fn01){ref-type="fn"}^ in March 2018. We downloaded mRNA expression (TCGA, RSEM normalization; ICGC, RPKM normalization) and clinical information. Samples with insufficient information (gene expression values and survival information) were excluded from the analysis. GSE11024 (Affymetrix U133 Plus 2.0 Array) ([@B19]), GSE12606 (Affymetrix U133 Plus 2.0 Array) ([@B29]), and GSE14762 (Affymetrix U133 Plus 2.0 Array) ([@B34]) were downloaded from GEO database using "GEOquery" R package. In the stage-related analysis, only the "Not Available (NA)" value of the stage was excluded. When the grade-related analysis was performed, only the "NA" value of the grade was excluded. These analyses were performed using R software version 3.5.0 ([@B25]).

To identify the differences of *TMED3* expression values between low stages (I and II) and high stages (III and IV), we performed Wilcoxon rank sum test using "coin" R package because the differences were not a normal distribution. We used Kruskal--Wallis test with Bonferroni adjustment to identify the differential expression of *TMED3* in different T stages using appropriate statistical methods (GSE11024 and GSE14762, Welch two sample *t*-test; GSE12606, paired *t*-test). Survival analyses were performed to predict overall survival (OS). We used three methods, (1) Uno's C-index in a time-dependent Area Under the Curve (AUC) analysis, (2) AUC values in receiver operating characteristics (ROC) at 5 years, and (3) Kaplan-Meier survival analysis, to evaluate the accuracy of the discrimination, as described previously ([@B4]; [@B11]). These values were obtained using the R packages "survival" and "survAUC." The C-index is a global measure of the fitness of a survival model for continuous event time in clinical studies ([@B32]; [@B17],[@B18]). In the Kaplan-Meier analyses, we determined the optimal cutoff value that had the maximal Uno's C-index by fivefold cross-validation ([Table 2](#T2){ref-type="table"}). We then used univariate and multivariate Cox regression to compare the effect of *TMED3* expression level as a categorical value on prognosis, along with other clinical variables. In the multivariate analysis with the stepwise selection, we included clinical factors that were not associated with survival in the univariate analysis. All statistical analyses were performed using R.

Results
=======

Overexpression of *TMED3*
-------------------------

The study included 446 patients from the TCGA and 91 patients from the ICGC ([@B12]; [@B13]; [@B3]; [@B1]; [@B26]). Patient information that was used in the current study is shown in [Table 1](#T1){ref-type="table"}. The expression of *TMED3* was compared between low (Stage I and II) and high stage (Stage III and IV) ccRCC patients in the TCGA and ICGC cohorts, and between low (Grade I and II) and high grade (Grade III and IV) ccRCC patients from the TCGA cohort. The *TMED3* expression levels in the high stage and grade cohorts were much higher than in the low stage and grade cohorts ([Figure 1](#F1){ref-type="fig"}). The groups with statistically significant *TMED3* differences were only two groups (T1 vs. T2 and T1 vs. T3 in TCGA) ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). Additionally, we confirmed *TMED3* expression in cancer tissues are higher than normal tissues by using GSE11024, GSE12606, and GSE14762) ([Supplementary Figure S2](#SM2){ref-type="supplementary-material"}).

###### 

Information on patients included in this study.

  Age (mean ± standard deviation)   TCGA 60.62 ± 12.80   ICGC 60.47 ± 10.03   
  --------------------------------- -------------------- -------------------- ----
  Gender                            Male                 290                  52
                                    Female               156                  39
  T stage                           T1                   221                  54
                                    T2                   57                   13
                                    T3                   161                  22
                                    T4                   7                    2
  N stage                           N0                   205                  79
                                    N1                   14                   2
  M stage                           M0                   376                  81
                                    M1                   70                   9
  TNM stage                         I                    216                  48
                                    II                   46                   12
                                    III                  111                  13
                                    IV                   71                   9
                                    NA                   2                    9
  Grade                             I                    9                    --
                                    II                   189                  --
                                    III                  175                  --
                                    IV                   68                   --
                                    NA                   5                    --
  Total patients                    446                  91                   

###### 

*TMED3* expression levels in the TCGA and ICGC cohorts.

            TCGA     ICGC       
  --------- -------- ---------- --------
  *TMED3*   Median   1299.2     19.921
            Mean     1478.6     21.891
            Cutoff   1360.708   23.942

![Comparison of *TMED3* gene expression between low (Stage I and II) and high stage (Stage III and IV) patients in the TCGA and ICGC ccRCC cohorts as well as the low (Grade I and II) and high grade (Grade III and IV) patients in the TCGA ccRCC cohort. **(A,B)** *TMED3* expression levels in ccRCC patients from the TCGA cohort. **(C)** *TMED3* expression levels in ccRCC cases from the ICGC cohort.](fgene-10-00355-g001){#F1}

Prognostic Value of *TMED3* Expression in ccRCC Patients
--------------------------------------------------------

To evaluate the prognostic value of *TMED3* in ccRCC, we analyzed Kaplan-Meier survival curves for *TMED3* gene expression and survival from the TCGA ([Figure 2](#F2){ref-type="fig"}) and ICGC ([Figure 3](#F3){ref-type="fig"}) cohorts. The high *TMED3* expression group had a significantly shorter survival than the low *TMED3* expression group in the TCGA ([Figure 2](#F2){ref-type="fig"}) and ICGC cohorts ([Figure 3](#F3){ref-type="fig"}). The prognostic value was further confirmed using multivariate analysis (*P* = 0.005 and 0.006 for the TCGA and ICGC cohorts, respectively; [Table 3](#T3){ref-type="table"}).

![Kaplan-Meier survival curves of ccRCC patients according to *TMED3* expression levels. Overall survival of all **(A)**, stage I and II **(B)**, stage III and IV **(C)**, grade I and II **(D)**, and grade III and IV **(E)** patients in the TCGA cohort.](fgene-10-00355-g002){#F2}

![Overall survival of all **(A)**, stage I and II **(B)**, and stage III and IV **(C)** patients in the ICGC cohort were examined according to *TMED3* gene expression levels. *P*-values were calculated by the log-rank test and are shown at the bottom left of each panel.](fgene-10-00355-g003){#F3}

###### 

Univariate and multivariate analysis of overall survival in each cohort.

  Variables                     Univariate cox regression   Multivariate cox regression (stepwise method)                                                   
  ----------------------------- --------------------------- ----------------------------------------------- ------- -------- -------------- ------- ------- -------
  **TCGA**                                                                                                                                                  
  TMED3                         \<0.001^∗∗∗^                1.927                                           1.388   2.674    0.036^∗^       1.614   1.031   2.526
  Age                           \<0.001^∗∗∗^                1.033                                           1.018   1.047    0.002^∗∗^      1.034   1.012   1.055
  Gender                        0.333                       0.850                                           0.612   1.181    --             --      --      --
  T stage (I, II vs. III, IV)   \<0.001^∗∗∗^                2.912                                           2.101   4.035    0.002^∗∗^      2.103   1.303   3.396
  N stage (0 vs. 1)             0.0011^∗∗^                  3.215                                           1.599   6.464    --             --      --      --
  M stage (0 vs. 1)             \<0.001^∗∗∗^                4.189                                           3.005   5.838    \<0.001^∗∗∗^   3.371   2.021   5.623
  **ICGC**                                                                                                                                                  
  TMED3                         \<0.001^∗∗∗^                3.612                                           1.756   7.429    \<0.001^∗∗∗^   3.543   1.718   7.306
  Age                           0.109                       1.031                                           0.993   1.071    --             --      --      --
  Gender                        0.863                       1.066                                           0.517   2.194    --             --      --      --
  T stage (I, II vs. III, IV)   \<0.001^∗∗∗^                3.786                                           1.838   7.801    \<0.001^∗∗∗^   4.165   2.011   8.628
  N stage (0 vs. 1)             0.444                       2.184                                           0.295   16.190   --             --      --      --
  M stage (0 vs. 1)             \<0.001^∗∗∗^                8.305                                           3.615   19.080   --             --      --      --
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indicate significance (\<0.05, \<0.01, and \<0.001).

To assess the utility of *TMED3* expression as a biomarker for ccRCC, we examined Uno's C-index in a time-dependent AUC analysis and the AUC values for ROCs at 5 years for the TCGA ([Figure 4](#F4){ref-type="fig"}) and ICGC cohorts ([Figure 5](#F5){ref-type="fig"}). *TMED3* had high C-index values in the two independent cohorts (TCGA: 0.610 and ICGC: 0.602; [Figure 4A](#F4){ref-type="fig"}, [5A](#F5){ref-type="fig"}, respectively). The 5-year ROC graphs also showed high AUC values for the TCGA and ICGC cohorts (TCGA: 0.579 and ICGC: 0.594; [Figure 4B](#F4){ref-type="fig"}, [5B](#F5){ref-type="fig"}, respectively).

![Time-dependent area under the curve (AUC) and receiver operating characteristic (ROC) curves at 5 years according to *TMED3* expression levels in the TCGA cohort. **(A)** Time-dependent AUC and **(B)** ROC curves at 5 years for patients in the TCGA cohort according to *TMED3* expression levels. C-index values are shown at the bottom right in **(A)**. AUC values at 5 years are shown at the bottom right in **(B)**.](fgene-10-00355-g004){#F4}

![Time-dependent area under the curve (AUC) and receiver operating characteristic (ROC) curves at 5 years according to *TMED3* expression levels in the ICGC cohort. **(A)** Time-dependent AUC and **(B)** ROC curves at 5 years for patients in the ICGC cohort according to *TMED3* expression levels. C-index values are shown at the bottom right in **(A)**. AUC values at 5 years are shown at the bottom right in **(B)**.](fgene-10-00355-g005){#F5}

Discussion
==========

The main purpose of our study is to strengthen the foundation of precision medicine by analyzing big genome data. There is a growing need to find novel prognostic genes for ccRCC. We analyzed the *TMED3* gene from two large independent cohorts as prognostic markers for ccRCC. In the present study, we confirmed that the *TMED3* gene fulfills a sufficient role as a universal prognostic marker for ccRCC. From survival analysis, we found a very good marker (*TMED3*) to predict the prognosis of renal cell carcinoma patients.

*TMED3* showed good predictive power in patients with low- and high-stage ccRCC, and low- and high-grade disease in the TCGA cohort and in patients with low- and high-stage cancer in the ICGC cohort ([Figure 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}). In addition, *TMED3* overexpression is associated with poor prognosis of ccRCC. A recent study showed that *TMED3* is overexpressed in HCC and that *TMED3* promotes HCC metastasis through IL-11/STAT3 signaling ([@B36]). Moreover, STAT3 activation is correlated with *TMED3* expression in HCC. Further, *TMED3* may contribute to the progression of colon cancer ([@B8]).

The current treatments for advanced ccRCC are VEGF, VEGFR and mammalian target of rapamycin (mTOR) ([@B33]) -- targeted therapy, but surgical treatment remains the most effective clinical therapy for ccRCC. The ccRCC can easily invade local tissues and metastasize ([@B35]). In addition, patients with RCC typically respond poorly to radiation and conventional chemotherapy ([@B21]) and ccRCC cells are unsatisfactory and resistant to currently available therapeutics. Further, the rates of recurrence and metastasis for ccRCC remain high due to long-term interactions with the microenvironment ([@B31]; [@B33]). Understanding the mechanisms underlying ccRCC pathogenesis will support the development of more effective therapeutic strategies, including new drugs and biomarkers. With recent advances in biotechnology, the field of bioinformatics has developed rapidly and more potential biomarkers have been discovered ([@B10]). There are a number of free databases available to the public, including GEO and TCGA databases that contain extensive gene expression data useful to finding heretofore unknown biomarkers and provide a wealth of information that can be used to identify biomarkers ([@B9]). These new molecular markers can be used in combination with the current staging systems.

Based on our findings in both cohorts, the higher the *TMED3* expression level, the worse the patient prognosis. Although there are limitations in transcriptome-based studies of *TMED3*, we believe that our results are sufficient to suggest the possibility of *TMED3* as a new prognostic biomarker for ccRCC.
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###### 

Comparison of *TMED3* gene expression according to T stages in the TCGA **(A)** and ICGC **(B)** ccRCC cohorts.

###### 

Click here for additional data file.

###### 

Comparison of TMED3 gene expression between cancer and normal kidney in GSE11024 **(A)**, GSE12606 **(B)**, and GSE14762 **(C)**.

###### 

Click here for additional data file.
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